Ubenimex
Specifications
58970-76-6CAS Number
261-529-2EC Number
(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acidIUPAC Name
C16H24N2O4Chemical Formula
308.37 g/molMolecular Weight
Bestatin; Ubenimex; 58970-76-6; NK-421; Ubenimexum; NK 421; I0J33N5627; NSC-265489; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-L-leucine; (3-Amino-2-hydroxy-4-phenylbutanoyl)-L-leucine; (S-(R*,S*))-N-(3-Amino-2-hydroxy-4-phenylbutyroyl)-L-leucine; L-Leucine, N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, (S-(R*,S*))-; (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; NSC265489; DTXSID4048430; (2S)-2-(((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)amino)-4-methylpentanoic acid; RefChem:900961; 3-amino-2-hydroxy-4-phenylbutyryl-L-leucine; 2-((3-amino-2-hydroxy-4-phenylbutanoyl)amino)-4-methylpentanoic acid; DTXCID0028404; (2R)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid; N-((2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl)-L-leucine; (S-(R*,S*))-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine; (2S)-2-(((2S,3R)-3-azaniumyl-2-hydroxy-4-phenylbutanoyl)amino)-4-methylpentanoate; (2S)-2-((2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoylamino)-4-methylpentanoic acid; 261-529-2; N-[(2S,3R)-3-Amino-2-hydroxy-1-oxo-4-phenylbutyl]-L-leucine; (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid; MFCD00083262; (-)-bestatin; N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine; CHEMBL29292; [(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine; Bestatin;Ubenimex; (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid; L-Leucine, N-[(2S,3R)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl]-; 2-(3-AMINO-2-HYDROXY-4-PHENYL-BUTYRYLAMINO)-4-METHYL-PENTANOIC ACID; Ubenimexum [Latin]; Ubenimex [INN:JAN]; (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid; SMR000059165; Bestatin (Ubenimex); EINECS 261-529-2; NSC 265489; BRN 4704312; Ubestatin; N-((2S,3R)-3-AMINO-2-HYDROXY-4-PHENYLBUTYRYL)-L-LEUCINE; Ubenimex, solid; L-LEUCINE, N-((2S,3R)-3-AMINO-2-HYDROXY-1-OXO-4-PHENYLBUTYL)-; UNII-I0J33N5627; 1txr; Ubenimex, Bestatin; 58970-76-6 (free base); [S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine; (-)-Bestatin; NK 421; NSC 265489; Ubenimex;; Bestatin (Standard); Ubenimex (Bestatin); Ubenimex (Bestatin)?; 3-(R)-Amino-2-(S)-hydroxy-4-phenylbutanoyl-(S)-leucine; UBENIMEX [INN]; UBENIMEX [JAN]; UBENIMEX [MI]; UBENIMEX [MART.]; UBENIMEX [WHO-DD]; SCHEMBL7944; Lopac0_000214; BSPBio_001553; KBioGR_000273; KBioSS_000273; MLS000028649; MLS001424177; MLS006010137; Ubenimex - Bio-X trade mark; orb1224557; orb1708791; BCBcMAP01_000178; BDBM23971; HY-B0134R; KBio2_000273; KBio2_002841; KBio2_005409; KBio3_000545; KBio3_000546; Bio2_000273; Bio2_000753; DTXSID301369975; GLXC-04737; HMS1361N15; HMS1791N15; HMS1989N15; HMS2052A03; HMS2232H13; HMS3268O06; HMS3402N15; HMS3412N16; HMS3676N16; HMS3715B20; N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine; (-)-N-((2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl)-L-leucine; EX-A1292; HY-B0134; BDBM50367209; EBC-17055; MSK163434; NSC779839; s1591; AKOS016339610; CCG-101071; CS-1910; DB03424; FU65199; KS-5207; NC00321; NSC-779839; SDCCGSBI-0050202.P003; IDI1_034023; SMP1_000030; NCGC00025323-01; NCGC00025323-02; NCGC00025323-03; NCGC00025323-04; NCGC00025323-05; NCGC00025323-06; NCGC00025323-08; NCGC00025323-11; NCGC00025323-14; BU164499; SY107271; NS00011810; ST50405897; U0111; U0618; AB00698345_05; EN300-7388593; SR-01000075724-3; BRD-K59574735-001-02-7; BRD-K59574735-001-05-0; BRD-K59574735-001-11-8; BRD-K59574735-001-12-6; Q10909912; Z2242062173; N-((2S,3R)-3-AMINO-2-HYDROXY-4-PHENYLBUTANOYL)-LEUCINE; N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine, 97%; (2S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino)-4-methylpentanoic aci d; (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoicacidSynonyms
